• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Antibiotic therapy for coronary heart disease: The myth and the reality.
【24h】

Antibiotic therapy for coronary heart disease: The myth and the reality.

机译：冠心病的抗生素治疗：神话与现实。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atherosclerosis is acknowledged as an active inflammatory and thrombotic disease, as opposed to simple degeneration. Infection with microorganisms may contribute to this inflammation and hence the atherosclerotic process. The "infective" hypothesis--first proposed more than a century ago by Virchow--has been revisited in recent years and has implicated numerous microorganisms as potential stimuli. The greatest body of evidence points to Chlamydia pneumoniae, a respiratory pathogen, as the "culprit" microorganism. Consistent finding of bacterial antigens, DNA and occasionally live "viable" organisms within human atherosclerotic plaque support the evidence for the concept linking C. pneumoniae to atherosclerosis. Although original seroepidemiological studies indicated an association, more recent prospective and larger studies suggest that there may be only a weak link between elevated antibodies and immune complexes to C. pneumoniae and coronary heart disease (CHD). Animal models have shown how atherogenesis can be induced by endovascular infection with C. pneumoniae; in vitro studies have explored various immunological and inflammatory pathways linking infection and atherothrombosis. On the basis of this, antibiotic trials have been explored to assess whether there is any role for antichlamydial agents in the treatment of cardiovascular events. Here, we focus on the main antibiotic studies and explores patient criteria and choice, duration of therapy, and whether effects on clinical events could be reduced.
机译：与简单变性相反，动脉粥样硬化被认为​​是一种活跃的炎症和血栓性疾病。感染微生物可能会导致这种炎症，进而导致动脉粥样硬化过程。 Virchow于一个多世纪前首次提出“感染性”假说，近年来已对其进行了重新研究，并将许多微生物作为潜在的刺激因素。最大的证据表明，呼吸道病原体肺炎衣原体是“罪魁祸首”微生物。在人类动脉粥样硬化斑块内发现细菌抗原，DNA和偶尔存在的“活”生物，这为将肺炎衣原体与动脉粥样硬化联系起来的概念提供了证据。尽管最初的流行病学研究表明存在这种关联，但最近的前瞻性研究和大型研究表明，升高的抗体与针对肺炎衣原体和冠心病（CHD）的免疫复合物之间可能只有微弱的联系。动物模型显示了如何通过肺炎衣原体的血管内感染诱导动脉粥样硬化。体外研究探索了各种与感染和动脉血栓形成有关的免疫和炎症途径。在此基础上，已经进行了抗生素试验，以评估抗衣原体药物在治疗心血管事件中是否有任何作用。在这里，我们专注于主要的抗生素研究，并探讨患者的标准和选择，治疗的持续时间以及是否可以减少对临床事件的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号